Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Clinical trial NCT06267560 · COMPLETED

Trial details

NCT number: NCT06267560
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease

Start date: 2024-04-24
Primary completion: 2026-03-25
Enrollment: 422

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.